Caribou Biosciences (CRBU)
Develops genome-edited allogeneic CAR-T candidates for blood cancers.
Something off on this page? Send us feedback.
Develops off-the-shelf allogeneic CAR-T candidates for blood cancers using its chRDNA genome-editing platform. Its active pipeline centers on vispa-cel for B-cell non-Hodgkin lymphoma and CB-011 for multiple myeloma.
Uses its chRDNA CRISPR platform to engineer off-the-shelf, donor-derived allogeneic CAR-T therapies. The platform supports multiplex editing, including approaches intended to improve persistence or immune evasion, rather than individualized autologous treatment.
Active development is concentrated in vispa-cel, an anti-CD19 candidate for relapsed or refractory B-cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA candidate for relapsed or refractory multiple myeloma. Neither candidate is approved, and the company has not commercialized a product or generated product-sales revenue. Its operating future depends on clinical development, regulatory interaction, manufacturing, funding, and development or commercialization revenue.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Nov 4, 2025 | Truist Financial | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $112.3M · Total debt $26.7M · Total assets $142.8M · Shareholders' equity $98.1M
- Revenue
- $1.5M
- Operating income
- −$25.3M
- Net income
- −$24.3M
No dividends on record.
| Institutions | ≈ 49.54% | 49.14M shares | |
|---|---|---|---|
| 145 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.81% | 1.80M shares | |
| 8 holders · as of Feb 27, 2026 | |||
| Other | ≈ 48.65% | 48.24M shares | |
| remainder | |||
99.18M company shares as of Aug 27, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (107.21M in the company's Sep 22, 2026 report, 99.18M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.88% | 7.82M | as of Jun 30, 2026 |
Pfizer IncInstitution | 4.73% | 4.69M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.24% | 4.21M | as of Jun 30, 2026 |
Mackenzie Financial CorpInstitution | 3.68% | 3.65M | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 2.80% | 2.77M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 25, 2026 | Timothy P. Kelly | officer: Chief Technology Officer | −6,228 | $1.93 |
| Feb 24, 2026 | Tina M. Albertson | officer: Chief Medical Officer | −1,066 | $1.96 |
| Feb 24, 2026 | Ruhi Ahmad Khan | officer: Chief Business Officer | −6,938 | $1.96 |
| Feb 24, 2026 | Barbara G. Mcclung | officer: Chief Legal Officer | −6,938 | $1.96 |
| Feb 24, 2026 | Timothy P. Kelly | officer: Chief Technology Officer | −3,147 | $1.96 |
- Allogene Therapeutics
Direct allogeneic CD19 CAR-T rival in large B-cell lymphoma
- CRISPR Therapeutics
Gene-edited allogeneic CD19 CAR-T rival in B-cell malignancies
- Gilead Sciences
Commercial autologous CD19 CAR-T supplier in B-cell lymphoma
- Bristol-Myers Squibb
Commercial BCMA CAR-T supplier in relapsed or refractory myeloma
- Legend Biotech (ADR)
Commercial BCMA CAR-T supplier in relapsed or refractory myeloma
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Caribou Biosciences | $1.35 | +3.85% | $128.9M | — | — | 12.8 | −43.8% |
| Allogene Therapeutics | $1.71 | +1.34% | $583.3M | — | — | 125.7 | — |
| CRISPR Therapeutics | $59.24 | +1.56% | $5.63B | — | — | 420.1 | +1,041.4% |
| Gilead Sciences | $152.74 | +1.45% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $62.35 | −0.43% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Legend Biotech (ADR) | $18.71 | +0.94% | $3.43B | — | 42.0 | 2.7 | +51.9% |
| Median | 13.8 | 16.8 | 6.1 | +31.1% |